<DOC>
	<DOCNO>NCT01778075</DOCNO>
	<brief_summary>The purpose study evaluate bioequivalence newly develop ULTRACET extended-release ( ER ) tablet tramadol hydrochloride acetaminophen , current market ULTRACET ER tablet , healthy participant fast condition .</brief_summary>
	<brief_title>A Study Assess Bioequivalence New ULTRACET Extended Release ( ER ) Tablet With Respect Marketed ULTRACET ER Tablet Under Fasted Condition</brief_title>
	<detailed_description />
	<mesh_term>Tramadol</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Signed informed consent document indicate understand purpose procedure require study willing participate Must agree use adequate contraception method deem appropriate investigator ( e.g. , vasectomy , doublebarrier , partner use effective contraception ) donate sperm study 3 month receive last dose study drug Body mass index ( weight [ kg ] /height2 [ ] 2 ) 18.5 30 kg/m2 ( inclusive ) , body weight less 50 kg Blood pressure ( participant sit 5 minute ) 90 140 mm Hg systolic , inclusive , high 90 mm Hg diastolic A 12lead electrocardiogram ( ECG ) consistent normal cardiac function , include sinus rhythm , pulse rate 45 90 bpm , QTc interval &lt; = 450 m , QRS interval &lt; 110 m , PR interval &lt; 200 m , morphology consistent healthy cardiac function History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic ( blood ) disease , coagulation disorder ( include abnormal bleeding ) , lipid abnormality , significant lung disease ( include bronchospastic respiratory disease ) , diabetes mellitus , kidney liver insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude participant could interfere interpretation study result Clinically significant abnormal value hematology , clinical chemistry urinalysis screen admission study center deem appropriate investigator Clinically significant abnormal physical examination , vital sign 12lead ECG screening ( admission study center ) deem appropriate investigator Use prescription nonprescription medication ( include vitamin herbal supplement ) , except oral contraceptive hormonal replacement therapy within 14 day first dose study drug schedule History , reason believe participant history , drug alcohol abuse within past 5 year</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Ultracet extend release ( ER )</keyword>
	<keyword>Tramadol hydrochloride</keyword>
	<keyword>Acetaminophen</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>